Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
| ▸ | GRM5 | P41594 | 4/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28238050 | 0.87 | SIGMAR1 (0.56) | SIGMAR1MKNK2CCNCCDK8 | |
| SCHEMBL3640363 | 0.87 | SIGMAR1 (0.73) | SIGMAR1GRM5MKNK2LMNAMAPK1 | |
| SCHEMBL2740504 | 0.85 | SIGMAR1 (0.61) | SIGMAR1GRM5 | |
| SCHEMBL4426054 | 0.85 | TACR2 (0.57) | SIGMAR1GRM5MKNK2 | |
| Hydrochloric Acid SCHEMBL223669 | 0.84 | SIGMAR1 (0.59) | SIGMAR1GRM5 | |
| SCHEMBL4417204 | 0.84 | SIGMAR1 (0.56) | SIGMAR1GRM5MKNK2CCNCCDK8 | |
| SCHEMBL8358286 | 0.83 | SIGMAR1 (0.76) | SIGMAR1LMNAMAPK1CCNCCDK8 | |
| SCHEMBL4413971 | 0.83 | GRM5 (0.76) | GRM5LMNAMAPK1RAB9A | |
| SCHEMBL4422998 | 0.83 | SIGMAR1 (0.55) | SIGMAR1GRM5CCNCCDK8 | |
| SCHEMBL4417079 | 0.82 | TSHR (0.76) | LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | SIGMAR1 413/4885GRM5 1/4885MKNK2 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.